
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of oral, small molecule protease inhibitors, presented three posters at the Western Society of Allergy, Asthma & Immunology 60th Annual Scientific Session in Kona, Hawaii.
The first poster highlighted that Konfident-S (NCT05505916) is a prospective trial to evaluate the effectiveness and safety of sebetralstat, an investigational oral plasma kallikrein inhibitor, for short-term prophylaxis (STP). The second reported phase 1 data evaluated the pharmacokinetic and pharmacodynamic parameters of sebetralstat in Japanese adults. These positive phase 1 data support the expansion of the Konfident phase 3 trial to Japan. Finally, KalVista presented a post hoc analysis of phase 2 trial data demonstrating that sebetralstat provided similar symptom relief, reduction in attack severity and use of rescue regardless of abdominal or peripheral attack location.
- Targeted Literature Review to Assess the Studies Supporting Short-Term Prophylactic Treatment Options for the Preprocedural Prevention of Attacks in Patients With Hereditary Angioedema: Dr. Marc A. Riedl, Division of Rheumatology, Allergy and Immunology, University of California San Diego
- Pharmacokinetic, Pharmacodynamic and Safety Profile of Sebetralstat in Healthy Japanese and White Adults: Results From a Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial: Matthew Iverson, KalVista Pharmaceuticals Inc., Cambridge, Massachusetts
- Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary Angioedema: Dr. Paul K. Audhya, KalVista Pharmaceuticals Inc., Cambridge, Massachusetts
Links to all posters and presentations can be found on the KalVista website under Publications.